Neurobrucellosis with thalamic infarction: a case report.
Brucellosis is prevalent in North and East Africa, the Middle East, South and Central Asia, South and Central America and the Mediterranean countries of Europe. In 5% of cases it may lead to central nervous system manifestation presenting most often as a meningitis or meningoencephalitis. Here we report and discuss a case of neurobrucellosis with meningitis with cranial nerves neuritis. A 56-year-old German male was admitted with bilateral abducens nerve palsy, amblyacousia and intractable headaches. An enzyme-linked immunosorbent assay (ELISA) revealed antibodies against Brucella in serum and cerebrospinal fluid (CSF). Additionally, our patient suffered from an infarction of the left thalamus. In conclusion, in cases of unresponsive meningitis or meningoencephalitis and history of travel in endemic regions, neurobrucellosis should be considered. If initial microbiological tests fail, complementary investigations such as ELISA are indicated to detect Brucella species in serum and/or CSF.
Jochum
Thomas
T
Department of Psychiatry, Friedrich-Schiller-University of Jena, Philosophenweg 3, 07743, Jena, Germany.
Kliesch
Uta
U
Both
Reinhard
R
Leonhardi
Jochen
J
Bär
Karl-Jürgen
KJ
D020434:Abducens Nerve Diseases / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D020520:Brain Infarction / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology*; D002002:Brucella / Q000276:immunology; D002006:Brucellosis / Q000150:complications*; D003389:Cranial Nerve Diseases / Q000382:microbiology / Q000503:physiopathology*; D004318:Doxycycline / Q000627:therapeutic use; D006261:Headache / Q000382:microbiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D016920:Meningitis, Bacterial / Q000382:microbiology / Q000503:physiopathology*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D012293:Rifampin / Q000627:therapeutic use; D013786:Thalamic Diseases / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D004318:Doxycycline; D012293:Rifampin; D008775:Methylprednisolone